SCHEMBL16737338

SCHEMBL16737338

CCOC(=O)CCc1cc(Br)ccn1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 2/20 0.45
▸ CYP4A11 Q02928 2/20 0.45
▸ EGFR P00533 1/20 0.43
▸ ERBB3 P21860 1/20 0.43
▸ LMNA P02545 2/20 0.41
▸ CYP1A2 P05177 1/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ SYK P43405 3/20 0.40
▸ MAPT P10636 1/20 0.40
▸ ALDH1A1 P00352 5/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ GAA P10253 2/20 0.39
▸ KDM4E B2RXH2 3/20 0.39
▸ HPGD P15428 2/20 0.39
▸ GLA P06280 1/20 0.39
▸ CASP1 P29466 1/20 0.39
▸ CASP7 P55210 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4082835 0.85 CYP4F2 (0.45) CYP4F2CYP4A11EGFRLMNASYK
SCHEMBL9952026 0.85 MEN1 (0.44) EGFRERBB3LMNAMAPTALDH1A1
SCHEMBL30163570 0.85 MEN1 (0.44) EGFRERBB3LMNAMAPTALDH1A1
SCHEMBL12815784 0.85 EGFR (0.46) EGFRLMNACYP1A2CYP3A4CYP2C19
SCHEMBL22166068 0.82 TNF (0.46) CYP4F2CYP4A11LMNASYKMAPT
SCHEMBL7768406 0.82 CYP4F2 (0.53) CYP4F2CYP4A11LMNASYKMAPT
SCHEMBL10743352 0.81 NOS1 (0.48) CYP4F2CYP4A11LMNASYKALDH1A1
Hydrochloric Acid SCHEMBL7766639 0.80 CYP4F2 (0.47) CYP4F2CYP4A11LMNASYKMAPT
SCHEMBL2771208 0.79 L3MBTL1 (0.53) CYP4F2CYP4A11LMNASYKMAPT
SCHEMBL2770972 0.79 CYP4F2 (0.42) CYP4F2CYP4A11LMNASYKMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025085560-A1 LYSINE ACETYLTRANSFERASE INHIBITORS Kronos Bio, Inc. (US) 2025-04-24 — — WO disclosed
EP-2863916-B1 SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS MERCK SHARP & DOHME (US) 2018-07-18 — — EP disclosed
EP-2863916-B1 SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS MERCK SHARP & DOHME (US) 2018-07-18 — — EP disclosed
US-9376418-B2 Substituted pyridine spleen tyrosine kinase (SYK) inhibitors MERCK SHARP & DOHME CORP. (US) 2016-06-28 — — US disclosed
US-9376418-B2 Substituted pyridine spleen tyrosine kinase (SYK) inhibitors MERCK SHARP & DOHME CORP. (US) 2016-06-28 — — US disclosed
US-9376418-B2 Substituted pyridine spleen tyrosine kinase (SYK) inhibitors MERCK SHARP & DOHME CORP. (US) 2016-06-28 — — US disclosed
US-20150148327-A1 SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS MERCK CANADA INC. (CA) 2015-05-28 — — US disclosed
US-20150148327-A1 SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS MERCK CANADA INC. (CA) 2015-05-28 — — US disclosed
US-20150148327-A1 SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS MERCK CANADA INC. (CA) 2015-05-28 — — US disclosed
EP-2863916-A1 SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS Merck Sharp & Dohme Corp. (US) 2015-04-29 — — EP disclosed
WO-2013192098-A1 SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS MERCK SHARP & DOHME CORP. (US) 2013-12-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148327-A1 SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (SYK) INHIBITORS SYK, BTK, LYN CYP4F2 1461/4885CYP4A11 1056/4885EGFR 517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback